** Jazz Pharmaceuticals' JAZZ.O shares rise 3% to $141.29
** Brokerage Morgan Stanley raises PT to $183 from $175, a 34.1% upside to the stock's last close; maintains "overweight" rating
** Says growth of Jazz's newer sleep disorder drug Xywav in H1 should offset ongoing switch from older drug Xyrem
** Sees 'meaningful expansion' opportunity for Jazz's breast cancer drug Ziihera
** Brokerage expects peak annual revenue of $240 million for brain tumor drug dordaviprone, Jazz's newly acquired drug from its buyout of Chimerix CMRX.O
** Six brokerages rate the stock "buy" or equivalent, one "neutral"; their median PT is $187.47, according to data compiled by LSEG
** JAZZ has risen 16.4% in the past 12 months
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。